Efficacy of Rizatriptan 10 mg Administered Early in a Migraine Attack

Abstract

Rizatriptan 10 mg was superior to placebo when treating migraine early, while pain is mild, as measured by pain freedom at 2 hours and 24-hour sustained pain freedom.

Sumatriptan: update and review

“…However, there are no head-to-head studies that directly compare the treatment paradigm of treating when the headache is moderate-to-severe, with treatment during the mild-headache phase of migraine. This has resulted in questions concerning the validity of this treatment approach by some academic headache specialists [45]. Other debates have centred on whether this treatment paradigm is the issue of either early intervention or intervention when the headache is mild.…”

Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: Application to patient-level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan

“…Adverse events associated with current acute therapies have been shown to result in delayed use by patients during acute attacks, which leads to inferior efficacy and higher levels of attack-related disability. The generally favorable tolerability of telcagepant could potentially help reduce this barrier to early treatment while pain is mild, a strategy that has been demonstrated to enhance outcomes and reduce disability with triptans (13)(14)(15)(16)(17)(18).…”

Current aspect of the diagnosis and management of migraine

“…[45] анализ всех приступов мигрени с ранним и позд-ним приемом триптанов показал, что ранний прием трипта-нов ассоциируется с достоверным уменьшением головной боли и увеличением периодов без болевой стадии. Отмечена лучшая эффективность триптанов при раннем приеме во время приступа мигрени [46][47][48]. Прием триптанов в тече-ние 1 ч после начала головной боли может предотвратить центральную сенситизацию [49].…”